Restoration of A2M reduces drug resistance and malignancy in paclitaxel-resistant lung cancer cells
- 8 May 2025
- journal article
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 185, 106789
Abstract
No abstract availableKeywords
Funding Information
- Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park (Z221100007422109)
- Wu Jieping Medical Foundation (32067502023-17-12)
- Beijing Municipal Administration of Hospitals (PX 2020016)
This publication has 38 references indexed in Scilit:
- Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022Cancer Innovation, 2023
- Acquisition of paclitaxel resistance modulates the biological traits of gastric cancer AGS cells and facilitates epithelial to mesenchymal transition and angiogenesisNaunyn-Schmiedeberg's Archives of Pharmacology, 2022
- SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)Clinical and Translational Oncology, 2018
- Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell linesBiomedicine & Pharmacotherapy, 2014
- Paclitaxel resistance by random mutagenesis of α‐tubulinCytoskeleton, 2013
- Activated α2 macroglobulin induces matrix metalloproteinase 9 expression by low‐density lipoprotein receptor‐related protein 1 through MAPK‐ERK1/2 and NF‐κB activation in macrophage‐derived cell linesJournal of Cellular Biochemistry, 2010
- Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancersDrug Resistance Updates, 2008
- Regional activation of chromosomal arm 7q with and without gene amplification in taxane‐selected human ovarian cancer cell linesGenes, Chromosomes and Cancer, 2005
- A Phase II Study of the Docetaxel–Carboplatin Chemotherapy Regimen in Advanced Non-Small-Cell Lung CancerLung, 2005
- Paclitaxel-induced cell deathCancer, 2000